Comparison of Different Adjuvant Therapies for 9 Resectable Cancer Types
暂无分享,去创建一个
[1] J. Kirkwood,et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Aki Vehtari,et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.
[3] J. Gong,et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[4] J. Padilla,et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Muti,et al. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials , 2010, Journal of experimental & clinical cancer research : CR.
[6] H. Mouridsen,et al. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high‐risk, premenopausal breast cancer , 2010, Cancer.
[7] C. Antonescu,et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.
[8] B. Vonen,et al. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group , 2009, Acta oncologica.
[9] L. Citrome,et al. Compelling or irrelevant? Using number needed to treat can help decide , 2008, Acta psychiatrica Scandinavica.
[10] R. Greil,et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer , 2007, British Journal of Cancer.
[11] M. Pino,et al. Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress? , 2007, Cancer.
[12] F. Ciardiello,et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] B. Nilsson,et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST) , 2007, British Journal of Cancer.
[14] Peter Neuhaus,et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. , 2007, JAMA.
[15] A. Jani. Approaching Clinical Problems in Prostate Cancer Radiotherapy Using the Number Needed to Treat (NNT) Technique , 2006, Cancer investigation.
[16] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[17] M. Ychou,et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Robert Livingston,et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.
[19] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[20] J. Kao,et al. Postprostatectomy adjuvant versus salvage radiotherapy , 2005, Cancer.
[21] B. Nilsson,et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.
[22] A. Dans,et al. Relative risk reduction , absolute risk reduction and number needed to treat , 2022 .
[23] Bengt Bergman,et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.
[24] J. Kao,et al. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma , 2003, Cancer.
[25] A. Basu,et al. Sentinel lymph node versus axillary lymph node dissection for early‐stage breast carcinoma , 2003, Cancer.
[26] M. Franchi,et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. , 2003, Journal of the National Cancer Institute.
[27] M. Parmar,et al. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma. , 2003, Journal of the National Cancer Institute.
[28] V. Sondak,et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] B. Nordlinger,et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial. , 2000, Annals of surgery.
[30] D G Altman,et al. Calculating the number needed to treat for trials where the outcome is time to an event , 1999, BMJ.
[31] I. Tusquets,et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S. Repše,et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] H. Rauschecker,et al. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. , 1997, European journal of cancer.
[34] D. Grignon,et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] R. Labianca,et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Hanna,et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] D L Sackett,et al. An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.
[38] M. Gore,et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Atac Secretariat. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002 .
[40] R. DeMatteo,et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.
[41] R. Sylvester,et al. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigators. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] D. Jaeck,et al. Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: A randomized study , 1993, Biotherapy.